Wilms Tumor 1 (WT1) Peptide Vaccine: Revision history

From Glioblastoma Treatments
Jump to navigationJump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

13 June 2024

31 March 2024

  • curprev 14:3014:30, 31 March 2024‎ Lazy talk contribs‎ 2,965 bytes +44‎ No edit summary
  • curprev 14:2714:27, 31 March 2024‎ Lazy talk contribs‎ 2,921 bytes +2,921‎ Created page with "{{TreatmentInfo |drug_name=Wilms Tumor 1 (WT1) Peptide Vaccine |FDA_approval=In clinical trials; not yet FDA-approved |used_for=Newly diagnosed and recurrent Glioblastoma Multiforme (GBM) |clinical_trial_phase=Phase II (Based on the latest clinical trial data available) |common_side_effects=Local erythema at the injection site; overall, the treatment is well-tolerated |OS_without=Typical median overall survival for GBM with standard treatment is about 15-17 months |OS_wi..."
Retrieved from "http://glioblastomatreatments.wiki:80/index.php?title=Wilms_Tumor_1_(WT1)_Peptide_Vaccine"